Sound Pharmaceuticals Inc., of Seattle, said it started enrollment in a phase Ib trial to test SPI-1005 in the treatment of Meniere's disease, or idiopathic endolymphatic hydrops, an inner ear disease that involves episodic vertigo, sensorineural hearing loss and tinnitus.